Metropolitan Life Insurance Company (MetLife)’s Royalty Pharma RPRX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,456	Closed	-$616K	–	2608
2021 Q4	$616K	Sell	15,456 -93	-0.6%	-$3.61K	0.01%	1284
2021 Q3	$562K	Buy	+15,549	New	+$604K	0.01%	1377
2021 Q2	–	Sell	-13,672	Closed	-$596K	–	2848
2021 Q1	$596K	Buy	13,672 +8,931	+188%	+$423K	0.01%	1314
2020 Q4	$237K	Buy	4,741 +946	+25%	+$40.1K	﹤0.01%	1822
2020 Q3	$160K	Buy	+3,795	New	+$163K	﹤0.01%	1923

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s RPRX Position: Q1 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Royalty Pharma (RPRX) in Q1 2022, closing a stake of 15,456 shares — an estimated $616K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in RPRX in Q3 2020 and held it in 5 quarters. The position peaked at $616K in Q4 2021. 279 funds tracked by Wall St. Rank hold RPRX as of Q1 2022.

Metropolitan Life Insurance Company (MetLife) reported no remaining Royalty Pharma position as of Q1 2022 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 15,456 Royalty Pharma shares in Q1 2022, an estimated $616K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Royalty Pharma in Q3 2020 and held it in 5 quarters.
Metropolitan Life Insurance Company (MetLife)'s Royalty Pharma position peaked at $616K in Q4 2021.
279 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2022, filed 12 May 2022.